23,338,039
Vote Records
27,979
Companies
11,817
Funds
4,051
Managers

Home › Companies › Heron Therapeutics, Inc. › 2025-2026

Heron Therapeutics, Inc. 2025-2026 Proxy Voting Records

Download data (CSV): ballot items · votes by manager · column guide.

Compiled from SEC Form N-PX filings and Heron Therapeutics, Inc.’s Form 8-K, filed June 16, 2026 (Item 5.07 on EDGAR). Page generated November 20, 2026.

  • 14Ballot items
  • 142Asset managers, any item
  • 1,780Fund votes
  • June 11, 2026Main meeting date

Results at a glance

Meeting of June 11, 2026: 12 items on Heron Therapeutics, Inc.’s Form 8-K, filed June 16, 2026: 5 approved · 7 passed (calculated).

Meeting of October 13, 2025: 2 items on Heron Therapeutics, Inc.’s Form 8-K, filed October 15, 2025: 2 approved.

Dissent

Notable dissent: 1 equity or compensation plan (15.5% against).

Dissent tiers, on the company’s own Form 8-K tally (support = FOR ÷ (FOR + AGAINST), or FOR ÷ (FOR + WITHHELD) on a withhold ballot; abstentions and broker non-votes excluded): shareholder proposals with 15% support or more are notable, 25% significant, 40% high; director nominees with 10% or more against or withheld are notable, 20% significant; say-on-pay under 80% support is notable, under 70% significant; equity and compensation plans with 15% or more against are notable, 25% significant; any other item the board put forward with 15% or more against is notable. How this is decided

Proxy season: 2023-2024 2024-2025 2025-2026

Activist investors: Rubric Capital (13D, 15.9%, as of October 17, 2025) · Clearline Capital (13F, 5.8%, as of September 30, 2026) · Tang Capital (13F, 4.7%, as of September 30, 2026)

Explore Heron Therapeutics, Inc. in the interactive database Compare manager voting policies

Official 2025-2026 meeting results reported by Heron Therapeutics, Inc.

These tallies are Heron Therapeutics, Inc.’s own, as disclosed to the U.S. Securities and Exchange Commission on Form 8-K, filed June 16, 2026 (Item 5.07, “Submission of Matters to a Vote of Security Holders”). They cover every share voted at the meeting, not just the funds that file Form N-PX. Heron Therapeutics, Inc. reported 2 meetings in this season; each is tabulated separately below, with its own filing.

Heron Therapeutics, Inc. — official shareholder meeting results, meeting held June 11, 2026 (Form 8-K, filed June 16, 2026)
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
Elect Director: Mr. Collard 87,289,7794,336,869185,208 --50,116,083 95%Passed (calculated)—
Elect Director: Mr. Cusack 88,537,7253,088,305185,826 --50,116,083 97%Passed (calculated)—
Elect Director: Dr. Dissanaike 87,960,0233,729,614122,219 --50,116,083 96%Passed (calculated)—
Elect Director: Mr. Johnson 87,703,8013,972,919135,136 --50,116,083 96%Passed (calculated)—
Elect Director: Mr. Kaseta 88,236,4083,424,597150,851 --50,116,083 96%Passed (calculated)—
Elect Director: Mr. Morgan 88,295,4373,381,282135,137 --50,116,083 96%Passed (calculated)—
Elect Director: Mr. Waage 85,276,8726,399,195135,789 --50,116,083 93%Passed (calculated)—
2. The appointment of Withum Smith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026 139,715,5141,706,193506,232 --0 99%Approved—
3. On a nonbinding advisory basis, the compensation paid to the Company's Named Executive Officers during the fiscal year ended December 31, 2025 77,315,47412,117,8612,378,521 --50,116,083 86%Approved—
4. The amendment and restatement of the Company's 2007 Amended and Restated Equity Incentive Plan, to, among other things, increase the number of shares of common stock authorized for issuance thereunder by an additional 16,560,000 shares 75,620,74113,846,0302,345,085 --50,116,083 85%Approved—
5. The amendment to the Company's 1997 Employee Stock Purchase Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by an additional 10,000,000 shares 83,765,9506,496,2051,549,701 --50,116,083 93%Approved—
6. On a nonbinding advisory basis, the adoption of the Tax Benefits Preservation Plan 88,182,8953,442,815186,146 --50,116,083 96%Approved—

Source: Heron Therapeutics, Inc., Form 8-K, filed with the SEC on June 16, 2026 — read the filing on EDGAR.

Heron Therapeutics, Inc. — official shareholder meeting results, meeting held October 13, 2025 (Form 8-K, filed October 15, 2025)
Ballot itemForAgainst AbstainWithheldBroker non-votesSupport (of votes cast)Reported outcomeVoting standard
1. Pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's Common Stock in connection with the conversion, at the option of the holder, of convertible senior unsecured promissory notes due 2031 held by several non-affiliate 89,632,2065,575,457218,161 --0 94%Approved—
2. Pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's Common Stock in connection with the automatic conversion of the Company's Series A Convertible Preferred Stock held by several non-affiliated holders, which could 91,534,6023,672,091219,131 --0 96%Approved—

Source: Heron Therapeutics, Inc., Form 8-K, filed with the SEC on October 15, 2025 — read the filing on EDGAR.

How asset managers voted at the Heron Therapeutics, Inc. 2025-2026 meetings

142 asset managers disclosed a vote on at least one Heron Therapeutics, Inc. item in their SEC Form N-PX filings. Each item below shows how many of them voted on it, and how. Share totals are the shares those managers' funds voted, summed across every fund they report.

Elect Director: Mr. Morgan

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Meeting held June 11, 2026.

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 88,295,437AGAINST: 3,381,282

Prior year: 98.5% for (June 12, 2025 meeting) ▼ 2.2 pts

Details: description as filed, official tally, votes by 36 asset managers

Description as filed by funds: To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Adam Morgan

Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Morgan”): 88,295,437 for, 3,381,282 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 10,026,037 for, 238,090 against, 1 abstained.

FOR
FOR: 10,026,037AGAINST: 238,090ABSTAIN: 1
Largest asset managers voting on “To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting ” at Heron Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,843,5155,512 10For
Charles Schwab1,378,5000 00For
State Street599,1220 00For
Jacob Funds Inc.304,486216,960 00Mixed
Goldman Sachs473,2720 00For
HIGHLAND GLOBAL ALLOCATION FUND232,8000 00For
Fidelity197,6390 00For
Equitable196,2830 00For
SEI164,8980 00For
BlackRock143,6060 00For
Lincoln Financial118,3920 00For
Global X73,8390 00For
Bridge Builder Trust68,5750 00For
Pacific Life57,5690 00For
Invesco44,1400 00For
Victory Capital21,2330 00For
ProShares19,2990 00For
AIG/SunAmerica17,3910 00For
Calvert015,618 00Against
T. Rowe Price13,9420 00For
Venerable Variable Insurance Trust12,6710 00For
Principal6,9780 00For
Brinker Capital Destinations Trust4,6790 00For
Nationwide4,4700 00For
Morgan Stanley4,1900 00For

Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).

Elect Director: Mr. Waage

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Meeting held June 11, 2026.

Combines 3 wordings of this item as funds reported it.

93% Majority: yes · of votes cast

FOR 93%
FOR: 85,276,872AGAINST: 6,399,195

Prior year: 94.4% for (June 12, 2025 meeting) ▼ 1.4 pts

Details: description as filed, official tally, votes by 36 asset managers

Description as filed by funds: To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Christian Waage

Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Waage”): 85,276,872 for, 6,399,195 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 8,380,271 for, 1,883,855 against, 1 abstained.

FORAGAINST
FOR: 8,380,271AGAINST: 1,883,855ABSTAIN: 1
Largest asset managers voting on “To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting ” at Heron Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,832,18716,839 10For
Charles Schwab01,378,500 00Against
State Street599,1220 00For
Jacob Funds Inc.304,486216,960 00Mixed
Goldman Sachs473,2720 00For
HIGHLAND GLOBAL ALLOCATION FUND232,8000 00For
Fidelity197,6390 00For
Equitable196,2830 00For
SEI0164,898 00Against
BlackRock143,6060 00For
Lincoln Financial118,3920 00For
Global X073,839 00Against
Bridge Builder Trust68,5750 00For
Pacific Life57,5690 00For
Invesco44,1400 00For
Victory Capital21,2330 00For
ProShares19,2990 00For
AIG/SunAmerica17,3910 00For
Calvert015,618 00Against
T. Rowe Price13,9420 00For
Venerable Variable Insurance Trust012,671 00Against
Principal6,9780 00For
Brinker Capital Destinations Trust4,6790 00For
Nationwide4,4700 00For
Morgan Stanley4,1900 00For

Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).

Elect Director: Mr. Collard

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Meeting held June 11, 2026.

Combines 3 wordings of this item as funds reported it.

95% Majority: yes · of votes cast

FOR 95%
FOR: 87,289,779AGAINST: 4,336,869

Prior year: 98.5% for (June 12, 2025 meeting) ▼ 3.2 pts

Details: description as filed, official tally, votes by 36 asset managers

Description as filed by funds: To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Craig Collard

Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Collard”): 87,289,779 for, 4,336,869 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 95% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 10,047,141 for, 216,984 against, 1 abstained.

FOR
FOR: 10,047,141AGAINST: 216,984ABSTAIN: 1
Largest asset managers voting on “To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting ” at Heron Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,849,00124 10For
Charles Schwab1,378,5000 00For
State Street599,1220 00For
Jacob Funds Inc.304,486216,960 00Mixed
Goldman Sachs473,2720 00For
HIGHLAND GLOBAL ALLOCATION FUND232,8000 00For
Fidelity197,6390 00For
Equitable196,2830 00For
SEI164,8980 00For
BlackRock143,6060 00For
Lincoln Financial118,3920 00For
Global X73,8390 00For
Bridge Builder Trust68,5750 00For
Pacific Life57,5690 00For
Invesco44,1400 00For
Victory Capital21,2330 00For
ProShares19,2990 00For
AIG/SunAmerica17,3910 00For
Calvert15,6180 00For
T. Rowe Price13,9420 00For
Venerable Variable Insurance Trust12,6710 00For
Principal6,9780 00For
Brinker Capital Destinations Trust4,6790 00For
Nationwide4,4700 00For
Morgan Stanley4,1900 00For

Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).

Elect Director: Mr. Johnson

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Meeting held June 11, 2026.

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 87,703,801AGAINST: 3,972,919

Prior year: 97.3% for (June 12, 2025 meeting) ▼ 1.6 pts

Details: description as filed, official tally, votes by 36 asset managers

Description as filed by funds: To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Craig Johnson

Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Johnson”): 87,703,801 for, 3,972,919 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 10,029,402 for, 234,724 against, 1 abstained.

FOR
FOR: 10,029,402AGAINST: 234,724ABSTAIN: 1
Largest asset managers voting on “To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting ” at Heron Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,832,19916,827 10For
Charles Schwab1,378,5000 00For
State Street599,1220 00For
Jacob Funds Inc.304,486216,960 00Mixed
Goldman Sachs473,2720 00For
HIGHLAND GLOBAL ALLOCATION FUND232,8000 00For
Fidelity197,6390 00For
Equitable196,2830 00For
SEI164,8980 00For
BlackRock143,6060 00For
Lincoln Financial118,3920 00For
Global X73,8390 00For
Bridge Builder Trust68,5750 00For
Pacific Life57,5690 00For
Invesco44,1400 00For
Victory Capital21,2330 00For
ProShares19,2990 00For
AIG/SunAmerica17,3910 00For
Calvert15,6180 00For
T. Rowe Price13,9420 00For
Venerable Variable Insurance Trust12,6710 00For
Principal6,9780 00For
Brinker Capital Destinations Trust4,6790 00For
Nationwide4,4700 00For
Morgan Stanley4,1900 00For

Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).

Elect Director: Mr. Kaseta

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Meeting held June 11, 2026.

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 88,236,408AGAINST: 3,424,597

Prior year: 97.4% for (June 12, 2025 meeting) ▼ 1.1 pts

Details: description as filed, official tally, votes by 36 asset managers

Description as filed by funds: To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Michael Kaseta

Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Kaseta”): 88,236,408 for, 3,424,597 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 10,047,148 for, 216,978 against, 1 abstained.

FOR
FOR: 10,047,148AGAINST: 216,978ABSTAIN: 1
Largest asset managers voting on “To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting ” at Heron Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,849,00818 10For
Charles Schwab1,378,5000 00For
State Street599,1220 00For
Jacob Funds Inc.304,486216,960 00Mixed
Goldman Sachs473,2720 00For
HIGHLAND GLOBAL ALLOCATION FUND232,8000 00For
Fidelity197,6390 00For
Equitable196,2830 00For
SEI164,8980 00For
BlackRock143,6060 00For
Lincoln Financial118,3920 00For
Global X73,8390 00For
Bridge Builder Trust68,5750 00For
Pacific Life57,5690 00For
Invesco44,1400 00For
Victory Capital21,2330 00For
ProShares19,2990 00For
AIG/SunAmerica17,3910 00For
Calvert15,6180 00For
T. Rowe Price13,9420 00For
Venerable Variable Insurance Trust12,6710 00For
Principal6,9780 00For
Brinker Capital Destinations Trust4,6790 00For
Nationwide4,4700 00For
Morgan Stanley4,1900 00For

Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).

Elect Director: Dr. Dissanaike

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Meeting held June 11, 2026.

Combines 3 wordings of this item as funds reported it.

96% Majority: yes · of votes cast

FOR 96%
FOR: 87,960,023AGAINST: 3,729,614

Prior year: 96.9% for (June 12, 2025 meeting) ▼ 0.9 pts

Details: description as filed, official tally, votes by 36 asset managers

Description as filed by funds: To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Sharmila Dissanaike, M.D., FACS, FCCM

Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Dr. Dissanaike”): 87,960,023 for, 3,729,614 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 10,232,767 for, 31,360 against.

FOR
FOR: 10,232,767AGAINST: 31,360
Largest asset managers voting on “To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting ” at Heron Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,837,69411,333 00For
Charles Schwab1,378,5000 00For
State Street599,1220 00For
Jacob Funds Inc.521,4460 00For
Goldman Sachs473,2720 00For
HIGHLAND GLOBAL ALLOCATION FUND232,8000 00For
Fidelity197,6390 00For
Equitable196,2830 00For
SEI164,8980 00For
BlackRock143,6060 00For
Lincoln Financial118,3920 00For
Global X73,8390 00For
Bridge Builder Trust68,5750 00For
Pacific Life57,5690 00For
Invesco44,1400 00For
Victory Capital21,2330 00For
ProShares19,2990 00For
AIG/SunAmerica17,3910 00For
Calvert015,618 00Against
T. Rowe Price13,9420 00For
Venerable Variable Insurance Trust12,6710 00For
Principal6,9780 00For
Brinker Capital Destinations Trust4,6790 00For
Nationwide4,4700 00For
Morgan Stanley4,1900 00For

Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).

Elect Director: Mr. Cusack

Calculated outcomeDIRECTOR ELECTIONSPassed (calculated)

Meeting held June 11, 2026.

Combines 3 wordings of this item as funds reported it.

97% Majority: yes · of votes cast

FOR 97%
FOR: 88,537,725AGAINST: 3,088,305
Details: description as filed, official tally, votes by 36 asset managers

Description as filed by funds: To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting of Stockholders and until their successors are duly elected and qualified or until their earlier death, resignation or removal: Tom Cusack

Heron Therapeutics, Inc.’s own tally for this item (“Elect Director: Mr. Cusack”): 88,537,725 for, 3,088,305 against, per its Form 8-K filed June 16, 2026 (Item 5.07). FOR was more than half of the votes cast. Whether the item passed is for the filing to say; its statement has not been read for this item.

Outcome: Passed (calculated) — The company’s filing reports the vote counts but does not state the outcome; we calculated it from the counts: votes for exceeded votes against.
Support: 97% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 10,047,148 for, 216,978 against, 1 abstained.

FOR
FOR: 10,047,148AGAINST: 216,978ABSTAIN: 1
Largest asset managers voting on “To elect seven director nominees named in the enclosed Proxy Statement to serve until the 2027 Annual Meeting ” at Heron Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,849,00818 10For
Charles Schwab1,378,5000 00For
State Street599,1220 00For
Jacob Funds Inc.304,486216,960 00Mixed
Goldman Sachs473,2720 00For
HIGHLAND GLOBAL ALLOCATION FUND232,8000 00For
Fidelity197,6390 00For
Equitable196,2830 00For
SEI164,8980 00For
BlackRock143,6060 00For
Lincoln Financial118,3920 00For
Global X73,8390 00For
Bridge Builder Trust68,5750 00For
Pacific Life57,5690 00For
Invesco44,1400 00For
Victory Capital21,2330 00For
ProShares19,2990 00For
AIG/SunAmerica17,3910 00For
Calvert15,6180 00For
T. Rowe Price13,9420 00For
Venerable Variable Insurance Trust12,6710 00For
Principal6,9780 00For
Brinker Capital Destinations Trust4,6790 00For
Nationwide4,4700 00For
Morgan Stanley4,1900 00For

Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).

Pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's Common Stock in connection…

Official resultCAPITAL STRUCTUREReported outcome: Approved

Meeting held October 13, 2025.

Combines 2 wordings of this item as funds reported it.

94% Approved · of votes cast

FOR 94%
FOR: 89,632,206AGAINST: 5,575,457
Details: description as filed, official tally, votes by 38 asset managers

Description as filed by funds: TO APPROVE, PURSUANT TO NASDAQ LISTING RULE 5635(D), THE ISSUANCE OF A NUMBER OF SHARES OF THE COMPANY'S COMMON STOCK IN CONNECTION WITH THE CONVERSION OF CONVERTIBLE SENIOR UNSECURED PROMISSORY NOTES DUE 2031 HELD BY SEVERAL NON-AFFILIATED PURCHASERS, WHICH COULD, UNDER CERTAIN CIRCUMSTANCES THAT MAY OCCUR IN THE FUTURE, EXCEED 19.99% OF THE NUMBER OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING PRIOR TO SUCH ISSUANCE.

Heron Therapeutics, Inc.’s own tally for this item (“1. Pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's Common Stock in connection with the conversion, at the option of the holder, of convertible senior unsecured promissory note”): 89,632,206 for, 5,575,457 against — passed, per its Form 8-K filed October 15, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “The votes with respect to each of the two proposals voted on at the Special Meeting are set forth below: Proposal 1: The Company's stockholders approved, pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's Common Stock in connection with the conversion, at t…”
Support: 94% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 38 asset managers below reported 11,738,277 for, 134,717 against.

FOR
FOR: 11,738,277AGAINST: 134,717
Largest asset managers voting on “TO APPROVE, PURSUANT TO NASDAQ LISTING RULE 5635(D), THE ISSUANCE OF A NUMBER OF SHARES OF THE COMPANY'S COMMO” at Heron Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,134,0000 00For
BlackRock1,933,1290 00For
T. Rowe Price1,324,9080 00For
Charles Schwab759,9550 00For
State Street652,7747,846 00For
TIAA323,4400 00For
Goldman Sachs275,9070 00For
HIGHLAND GLOBAL ALLOCATION FUND232,8000 00For
SEI141,8150 00For
Lincoln Financial0118,392 00Against
QUANTITATIVE MASTER SERIES LLC103,6570 00For
Fidelity90,5970 00For
AIG/SunAmerica79,5930 00For
Equitable79,0230 00For
John Hancock78,6830 00For
Global X75,6370 00For
Bridge Builder Trust69,4780 00For
Pacific Life67,9200 00For
PACE SELECT ADVISORS TRUST62,6000 00For
Brighthouse56,0190 00For
Voya36,6330 00For
ProShares34,4030 00For
Jacob Funds Inc.32,9410 00For
MASTER INVESTMENT PORTFOLIO22,9920 00For
Calvert15,6180 00For

Showing the 25 largest of 38 asset managers. All 38 are in the interactive database (link above).

Pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's Common Stock in connection…

Official resultCAPITAL STRUCTUREReported outcome: Approved

Meeting held October 13, 2025.

Combines 2 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 91,534,602AGAINST: 3,672,091
Details: description as filed, official tally, votes by 38 asset managers

Description as filed by funds: TO APPROVE, PURSUANT TO NASDAQ LISTING RULE 5635(D), THE ISSUANCE OF A NUMBER OF SHARES OF THE COMPANY'S COMMON STOCK IN CONNECTION WITH THE CONVERSION OF THE COMPANY'S SERIES A CONVERTIBLE PREFERRED STOCK HELD BY SEVERAL NON-AFFILIATED HOLDERS, WHICH COULD, UNDER CERTAIN CIRCUMSTANCES THAT MAY OCCUR IN THE FUTURE, EXCEED 19.99% OF THE NUMBER OF SHARES OF COMMON STOCK ISSUED AND OUTSTANDING PRIOR TO SUCH ISSUANCE.

Heron Therapeutics, Inc.’s own tally for this item (“2. Pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's Common Stock in connection with the automatic conversion of the Company's Series A Convertible Preferred Stock held by sever”): 91,534,602 for, 3,672,091 against — passed, per its Form 8-K filed October 15, 2025 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: The Company's stockholders approved, pursuant to Nasdaq Listing Rule 5635(d), the issuance of a number of shares of the Company's Common Stock in connection with the automatic conversion of the Company's Series A Convertible Preferred Stock held by several non-affiliated holders, which …”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 38 asset managers below reported 11,872,994 for.

FOR
FOR: 11,872,994
Largest asset managers voting on “TO APPROVE, PURSUANT TO NASDAQ LISTING RULE 5635(D), THE ISSUANCE OF A NUMBER OF SHARES OF THE COMPANY'S COMMO” at Heron Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,134,0000 00For
BlackRock1,933,1290 00For
T. Rowe Price1,324,9080 00For
Charles Schwab759,9550 00For
State Street660,6200 00For
TIAA323,4400 00For
Goldman Sachs275,9070 00For
HIGHLAND GLOBAL ALLOCATION FUND232,8000 00For
SEI141,8150 00For
Lincoln Financial118,3920 00For
QUANTITATIVE MASTER SERIES LLC103,6570 00For
Fidelity90,5970 00For
AIG/SunAmerica79,5930 00For
Equitable79,0230 00For
John Hancock78,6830 00For
Global X75,6370 00For
Bridge Builder Trust69,4780 00For
Pacific Life67,9200 00For
PACE SELECT ADVISORS TRUST62,6000 00For
Brighthouse56,0190 00For
Voya36,6330 00For
ProShares34,4030 00For
Jacob Funds Inc.32,9410 00For
MASTER INVESTMENT PORTFOLIO22,9920 00For
Calvert15,6180 00For

Showing the 25 largest of 38 asset managers. All 38 are in the interactive database (link above).

The amendment to the Company's 1997 Employee Stock Purchase Plan, as amended, to increase the number of shares of…

Official resultCOMPENSATIONReported outcome: Approved

Meeting held June 11, 2026.

Combines 2 wordings of this item as funds reported it.

93% Approved · of votes cast

FOR 93%
FOR: 83,765,950AGAINST: 6,496,205
Details: description as filed, official tally, votes by 36 asset managers

Description as filed by funds: TO AMEND THE COMPANY'S 1997 EMPLOYEE STOCK PURCHASE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER BY AN ADDITIONAL 10,000,000 SHARES.

Heron Therapeutics, Inc.’s own tally for this item (“5. The amendment to the Company's 1997 Employee Stock Purchase Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by an additional 10,000,000 shares”): 83,765,950 for, 6,496,205 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 5: The Company's stockholders approved the amendment to the Company's 1997 Employee Stock Purchase Plan, as amended, to increase the number of shares of common stock authorized for issuance thereunder by an additional 10,000,000 shares:”
Support: 93% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 10,047,117 for, 217,000 against, 10 abstained.

FOR
FOR: 10,047,117AGAINST: 217,000ABSTAIN: 10
Largest asset managers voting on “TO AMEND THE COMPANY'S 1997 EMPLOYEE STOCK PURCHASE PLAN, AS AMENDED, TO INCREASE THE NUMBER OF SHARES OF COMM” at Heron Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,848,97740 100For
Charles Schwab1,378,5000 00For
State Street599,1220 00For
Jacob Funds Inc.304,486216,960 00Mixed
Goldman Sachs473,2720 00For
HIGHLAND GLOBAL ALLOCATION FUND232,8000 00For
Fidelity197,6390 00For
Equitable196,2830 00For
SEI164,8980 00For
BlackRock143,6060 00For
Lincoln Financial118,3920 00For
Global X73,8390 00For
Bridge Builder Trust68,5750 00For
Pacific Life57,5690 00For
Invesco44,1400 00For
Victory Capital21,2330 00For
ProShares19,2990 00For
AIG/SunAmerica17,3910 00For
Calvert15,6180 00For
T. Rowe Price13,9420 00For
Venerable Variable Insurance Trust12,6710 00For
Principal6,9780 00For
Brinker Capital Destinations Trust4,6790 00For
Nationwide4,4700 00For
Morgan Stanley4,1900 00For

Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).

The amendment and restatement of the Company's 2007 Amended and Restated Equity Incentive Plan, to, among other things…

Official resultCOMPENSATIONReported outcome: Approved

Meeting held June 11, 2026.

Combines 2 wordings of this item as funds reported it.

85% Approved · of votes cast

FOR 85%AGAINST
FOR: 75,620,741AGAINST: 13,846,030
Details: description as filed, official tally, votes by 36 asset managers

Description as filed by funds: TO APPROVE THE AMENDMENT AND RESTATEMENT OF THE COMPANY'S 2007 AMENDED AND RESTATED EQUITY INCENTIVE PLAN, TO, AMONG OTHER THINGS, INCREASE THE NUMBER OF SHARES OF COMMON STOCK AUTHORIZED FOR ISSUANCE THEREUNDER BY AN ADDITIONAL 16,560,000 SHARES.

Heron Therapeutics, Inc.’s own tally for this item (“4. The amendment and restatement of the Company's 2007 Amended and Restated Equity Incentive Plan, to, among other things, increase the number of shares of common stock authorized for issuance thereunder by an additional”): 75,620,741 for, 13,846,030 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 4: The Company's stockholders approved the amendment and restatement of the Company's 2007 Amended and Restated Equity Incentive Plan, to, among other things, increase the number of shares of common stock authorized for issuance thereunder by an additional 16,560,000 shares:”
Support: 85% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 9,029,248 for, 1,234,863 against, 16 abstained.

FOR
FOR: 9,029,248AGAINST: 1,234,863ABSTAIN: 16
Largest asset managers voting on “TO APPROVE THE AMENDMENT AND RESTATEMENT OF THE COMPANY'S 2007 AMENDED AND RESTATED EQUITY INCENTIVE PLAN, TO,” at Heron Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,837,63311,378 160For
Charles Schwab1,378,5000 00For
State Street0599,122 00Against
Jacob Funds Inc.304,486216,960 00Mixed
Goldman Sachs473,2720 00For
HIGHLAND GLOBAL ALLOCATION FUND232,8000 00For
Fidelity197,6381 00For
Equitable75,213121,070 00Mixed
SEI164,8980 00For
BlackRock143,6060 00For
Lincoln Financial0118,392 00Against
Global X73,8390 00For
Bridge Builder Trust68,5750 00For
Pacific Life57,5690 00For
Invesco044,140 00Against
Victory Capital021,233 00Against
ProShares019,299 00Against
AIG/SunAmerica017,391 00Against
Calvert015,618 00Against
T. Rowe Price013,942 00Against
Venerable Variable Insurance Trust12,6710 00For
Principal06,978 00Against
Brinker Capital Destinations Trust04,679 00Against
Nationwide4,4700 00For
Morgan Stanley04,190 00Against

Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).

On a nonbinding advisory basis, the adoption of the Tax Benefits Preservation Plan

Official resultOTHERReported outcome: Approved

Meeting held June 11, 2026.

Combines 2 wordings of this item as funds reported it.

96% Approved · of votes cast

FOR 96%
FOR: 88,182,895AGAINST: 3,442,815
Details: description as filed, official tally, votes by 36 asset managers

Description as filed by funds: TO RATIFY, ON A NONBINDING ADVISORY BASIS, THE ADOPTION OF THE TAX BENEFITS PRESERVATION PLAN.

Heron Therapeutics, Inc.’s own tally for this item (“6. On a nonbinding advisory basis, the adoption of the Tax Benefits Preservation Plan”): 88,182,895 for, 3,442,815 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 6: The Company's stockholders ratified, on a nonbinding advisory basis, the adoption of the Tax Benefits Preservation Plan:”
Support: 96% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 9,900,066 for, 364,060 against, 1 abstained.

FOR
FOR: 9,900,066AGAINST: 364,060ABSTAIN: 1
Largest asset managers voting on “TO RATIFY, ON A NONBINDING ADVISORY BASIS, THE ADOPTION OF THE TAX BENEFITS PRESERVATION PLAN.” at Heron Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,849,00719 10For
Charles Schwab1,378,5000 00For
State Street592,8546,268 00For
Jacob Funds Inc.304,486216,960 00Mixed
Goldman Sachs473,2720 00For
HIGHLAND GLOBAL ALLOCATION FUND232,8000 00For
Fidelity197,6390 00For
Equitable196,2830 00For
SEI164,8980 00For
BlackRock143,6060 00For
Lincoln Financial0118,392 00Against
Global X73,8390 00For
Bridge Builder Trust68,5750 00For
Pacific Life57,5690 00For
Invesco44,1400 00For
Victory Capital21,2330 00For
ProShares19,2990 00For
AIG/SunAmerica17,3910 00For
Calvert15,6180 00For
T. Rowe Price013,942 00Against
Venerable Variable Insurance Trust12,6710 00For
Principal6,9780 00For
Brinker Capital Destinations Trust04,679 00Against
Nationwide4,4700 00For
Morgan Stanley4,1900 00For

Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).

On a nonbinding advisory basis, the compensation paid to the Company's Named Executive Officers during the fiscal year…

Official resultFund totals may overlapSECTION 14A SAY-ON-PAY VOTESReported outcome: Approved

Meeting held June 11, 2026.

Combines 7 wordings of this item as funds reported it.

86% Approved · of votes cast

FOR 86%
FOR: 77,315,474AGAINST: 12,117,861

Prior year: 95.7% for (June 12, 2025 meeting) ▼ 9.3 pts

Details: description as filed, official tally, votes by 139 asset managers

Description as filed by funds: TO APPROVE, ON A NONBINDING ADVISORY BASIS, COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS DURING THE FISCAL YEAR ENDED DECEMBER 31, 2025.

Heron Therapeutics, Inc.’s own tally for this item (“3. On a nonbinding advisory basis, the compensation paid to the Company's Named Executive Officers during the fiscal year ended December 31, 2025”): 77,315,474 for, 12,117,861 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 3: The Company's stockholders approved, on a nonbinding advisory basis, the compensation paid to the Company's Named Executive Officers during the fiscal year ended December 31, 2025:”
Support: 86% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

Fund voting reports and institutional-manager reports both cover this item. An institutional manager can report shares that a fund it advises also reports, so the two are shown separately below and never added together, and their sum is not shown (fund and manager reports combined may count the same shares twice).

Fund voting reports: 36 asset managers voting on “TO APPROVE, ON A NONBINDING ADVISORY BASIS, COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS DURING THE FISCA” at Heron Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,843,4435,570 160For
Charles Schwab1,378,5000 00For
State Street599,1220 00For
Jacob Funds Inc.304,486216,960 00Mixed
Goldman Sachs473,2720 00For
HIGHLAND GLOBAL ALLOCATION FUND0232,800 00Against
Fidelity197,6390 00For
Equitable196,2830 00For
SEI0164,898 00Against
BlackRock143,6060 00For
Lincoln Financial118,3920 00For
Global X073,839 00Against
Bridge Builder Trust68,5750 00For
Pacific Life57,5690 00For
Invesco44,1400 00For
Victory Capital21,2330 00For
ProShares19,2990 00For
AIG/SunAmerica17,3910 00For
Calvert15,6180 00For
T. Rowe Price13,9420 00For
Venerable Variable Insurance Trust012,671 00Against
Principal6,9780 00For
Brinker Capital Destinations Trust4,6790 00For
Nationwide4,4700 00For
Morgan Stanley4,1900 00For

Fund voting reports, all 36 managers: 9,557,334 for, 706,779 against, 16 abstained. Showing the 25 largest; every one is in the interactive database (link above).

Institutional-manager reports: 113 asset managers voting on “TO APPROVE, ON A NONBINDING ADVISORY BASIS, COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS DURING THE FISCA” at Heron Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Rubric Capital Management LP26,713,5030 00For
Clearline Capital LP11,586,1160 00For
Velan Capital Investment Management LP10,519,8360 00For
ORBIMED ADVISORS LLC06,127,998 00Against
PALISADE CAPITAL MANAGEMENT, LP2,391,6180 00For
BlackRock1,795,0414,424 00For
State Street1,413,66711,064 00For
Stonepine Capital Management, LLC1,402,1910 00For
Charles Schwab1,379,0480 00For
Northern Trust605,7104,681 00For
Orchard Capital Management, LLC0458,766 00Against
AQR414,9020 00For
MELLON INVESTMENTS Corp377,3470 00For
GEODE CAPITAL MANAGEMENT, LLC358,9200 00For
Renaissance251,8920 00For
DE Shaw246,4040 00For
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM0243,570 00Against
NexPoint Advisors, L.P.0242,950 00Against
Goldman Sachs215,2600 00For
AllianceBernstein198,5500 00For
Vanguard170,6740 00For
SEI0165,009 00Against
PNC BANK, NATIONAL ASSOCIATION081,818 00Against
NEW YORK STATE COMMON RETIREMENT FUND076,616 00Against
STIFEL NICOLAUS & CO INC \MO\75,0620 00For

Institutional-manager reports, all 113 managers: 60,802,334 for, 7,593,382 against. Showing the 25 largest; every one is in the interactive database (link above).

The appointment of Withum Smith+Brown, PC as the Company's independent registered public accounting firm for the fiscal…

Official resultAUDIT-RELATEDReported outcome: Approved

Meeting held June 11, 2026.

99% Approved · of votes cast

FOR 99%
FOR: 139,715,514AGAINST: 1,706,193

Prior year: 99.1% for (June 12, 2025 meeting) ▼ 0.3 pts

Details: description as filed, official tally, votes by 36 asset managers

Description as filed by funds: TO RATIFY THE APPOINTMENT OF WITHUM AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR ENDING DECEMBER 31, 2026.

Heron Therapeutics, Inc.’s own tally for this item (“2. The appointment of Withum Smith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026”): 139,715,514 for, 1,706,193 against — passed, per its Form 8-K filed June 16, 2026 (Item 5.07).

Reported outcome: Approved, in the filing’s own words: “Proposal 2: The Company's stockholders ratified the appointment of Withum Smith+Brown, PC as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026:”
Support: 99% of votes cast — FOR ÷ (FOR + AGAINST); abstentions and broker non-votes are excluded.

The 36 asset managers below reported 10,258,627 for, 5,500 against, 1 abstained.

FOR
FOR: 10,258,627AGAINST: 5,500ABSTAIN: 1
Largest asset managers voting on “TO RATIFY THE APPOINTMENT OF WITHUM AS OUR INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM FOR THE FISCAL YEAR E” at Heron Therapeutics, Inc., 2025-2026
Asset managerForAgainst AbstainWithheldVote
Vanguard5,843,5275,500 10For
Charles Schwab1,378,5000 00For
State Street599,1220 00For
Jacob Funds Inc.521,4460 00For
Goldman Sachs473,2720 00For
HIGHLAND GLOBAL ALLOCATION FUND232,8000 00For
Fidelity197,6390 00For
Equitable196,2830 00For
SEI164,8980 00For
BlackRock143,6060 00For
Lincoln Financial118,3920 00For
Global X73,8390 00For
Bridge Builder Trust68,5750 00For
Pacific Life57,5690 00For
Invesco44,1400 00For
Victory Capital21,2330 00For
ProShares19,2990 00For
AIG/SunAmerica17,3910 00For
Calvert15,6180 00For
T. Rowe Price13,9420 00For
Venerable Variable Insurance Trust12,6710 00For
Principal6,9780 00For
Brinker Capital Destinations Trust4,6790 00For
Nationwide4,4700 00For
Morgan Stanley4,1900 00For

Showing the 25 largest of 36 asset managers. All 36 are in the interactive database (link above).

Largest Heron Therapeutics, Inc. shareholders voting in 2025-2026

Ranked separately for each type of Form N-PX report. An institutional manager can report shares that a fund it advises also reports, so the two tables can list the same shares and are never added together. Each is ranked by the shares voted on the item that the most managers of that type reported, shown as a share of the 189,279,369 shares outstanding at the time of that meeting.

Fund voting reports: top Heron Therapeutics, Inc. shareholders by shares voted on “TO APPROVE, PURSUANT TO NASDAQ LISTING RULE 5635(D), THE ISSUANCE OF A NUMBER OF SHARES OF THE…”, 2025-2026
#Asset manager % of shares outstanding
1Vanguard 2.71%
2BlackRock 1.02%
3T. Rowe Price 0.70%
4Charles Schwab 0.40%
5State Street 0.35%
6TIAA 0.17%
7Goldman Sachs 0.15%
8HIGHLAND GLOBAL ALLOCATION FUND 0.12%
9SEI 0.07%
10Lincoln Financial 0.06%
Institutional-manager reports: top Heron Therapeutics, Inc. shareholders by shares voted on “TO APPROVE, ON A NONBINDING ADVISORY BASIS, COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS…”, 2025-2026
#Asset manager % of shares outstanding
1Rubric Capital Management LP 14.11%
2Clearline Capital LP 6.12%
3Velan Capital Investment Management LP 5.56%
4ORBIMED ADVISORS LLC 3.24%
5PALISADE CAPITAL MANAGEMENT, LP 1.26%
6BlackRock 0.95%
7State Street 0.75%
8Stonepine Capital Management, LLC 0.74%
9Charles Schwab 0.73%
10Northern Trust 0.32%

Reported Heron Therapeutics, Inc. holdings and ownership

As disclosed to the SEC in Form 13F (quarter-end holdings of 30 large managers), Schedules 13D and 13G (beneficial ownership above 5%) and the company’s own proxy statement (DEF 14A). Each row gives its source and the date its figure is as of: for Form 13F the quarter end it reports, for Schedules 13D and 13G the filing date, and for the proxy statement the date of its ownership table (or, where that date has not been read, the date the proxy was filed). The rows are therefore not all as of the same day.

Heron Therapeutics, Inc. holdings and ownership disclosed for the 2025-2026 proxy season, with each row’s source and date
HolderShares % outstandingSource, as of
Rubric Capital Management LP30,046,828 15.87%Proxy statement (DEF 14A), proxy filed April 30, 2026
Clearline Capital, L.P.12,235,239 6.46%Proxy statement (DEF 14A), proxy filed April 30, 2026
Current Executive Officers and Directors as a group (10 persons)11,586,424 6.12%Proxy statement (DEF 14A), proxy filed April 30, 2026
BlackRock10,106,422 5.34%Form 13F, quarter ended March 31, 2026
Subsidiaries or business divisions of Vanguard Group Inc.9,820,384 5.19%Proxy statement (DEF 14A), proxy filed April 30, 2026
Vanguard Group9,820,384 5.19%Form 13F, quarter ended March 31, 2026
Adam Morgan9,443,929 4.99%Proxy statement (DEF 14A), proxy filed April 30, 2026
Millennium Management7,630,527 4.03%Form 13F, quarter ended March 31, 2026
Geode Capital4,010,087 2.12%Form 13F, quarter ended March 31, 2026
State Street3,843,672 2.03%Form 13F, quarter ended March 31, 2026

Percentages above are of 189,279,369 shares outstanding, as reported by Heron Therapeutics, Inc. on its Form 10-Q dated May 6, 2026 (see the filing on EDGAR). This is the count contemporaneous with the 2025-2026 meeting, not today’s. Each holding is as of its own filing, which may be dated before or after the meeting.

About this meeting

At Heron Therapeutics, Inc.'s 2 shareholder meetings in the 2025-2026 proxy season (held October 13, 2025 and June 11, 2026), 142 asset managers reported votes on at least one of its 14 ballot items in their SEC Form N-PX filings, covering 1,780 separate fund positions. On the most widely held item of the season, voted at the meeting held June 11, 2026 — TO APPROVE, ON A NONBINDING ADVISORY BASIS, COMPENSATION PAID TO OUR NAMED EXECUTIVE OFFICERS… — Heron Therapeutics, Inc.'s filing reports the proposal as approved, with 86% support of the votes cast (FOR divided by FOR plus AGAINST, the conventional basis for proxy support; abstentions, broker non-votes and unvoted shares are excluded because none of them took a side). Source: Heron Therapeutics, Inc.'s Form 8-K, Item 5.07, filed with the U.S. Securities and Exchange Commission on June 16, 2026.

Related

About this page

Every figure above is derived from filings made with the US Securities and Exchange Commission: Form N-PX, in which registered funds disclose how they voted every proxy and institutional managers disclose their votes on executive pay (say-on-pay, say-on-frequency and golden parachutes), and Form 8-K Item 5.07, in which the company reports its own meeting results. Shares outstanding are taken from Heron Therapeutics, Inc.’s 10-Q dated May 6, 2026. This page is a static snapshot rebuilt weekly on November 20, 2026; a live search always shows the current data.

Heron Therapeutics, Inc. proxy season coverage: 2023-2024 · 2024-2025 · 2025-2026 (this page).

Cite this page

Proxy Votes Now, “Heron Therapeutics (HRTX) 2025-2026 Annual & Special Meetings”, https://proxyvotesnow.com/company/heron-therapeutics-inc/2026 (version of November 20, 2026). Derived from SEC Form N-PX and Form 8-K filings; tables licensed CC BY 4.0. Licence: CC BY 4.0.